Key result
The presence of both metabolic syndrome and significant coronary artery disease was associated with the lowest serum adiponectin levels (6.7±3.8 µg/ml) compared to neither condition (12.1±8.3 µg/ml; p<0.001).
Why the study?
Is low serum adiponectin independently associated with metabolic syndrome and coronary atherosclerosis in patients undergoing coronary angiography?
Cross-Sectional (n=687)
Is low serum adiponectin independently associated with metabolic syndrome and coronary atherosclerosis in patients undergoing coronary angiography?
Absolute Event Rate: 6.7% vs 12.1%
p-value: p=<0.001
Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Supports adiponectin as potential biomarker for combined metabolic and coronary risk; hypothesis-generating and requires prospective validation before clinical use.
Saely et al. (2007) conducted a cross-sectional in Metabolic syndrome and coronary artery disease (n=687). Metabolic syndrome and significant coronary artery disease vs. Neither metabolic syndrome nor significant coronary artery disease was evaluated on Serum adiponectin levels (µg/ml) (p=<0.001). The presence of both metabolic syndrome and significant coronary artery disease was associated with the lowest serum adiponectin levels (6.7±3.8 µg/ml) compared to neither condition (12.1±8.3 µg/ml; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: